Top 5 HIV treatment stories from CROI 2023
Integrase inhibitors do not raise cardiovascular risk in people starting HIV treatment
After viral rebound, dolutegravir-based treatment more likely to suppress HIV
Integrase inhibitors raise the risk of heart attack, stroke during first two years of treatment
How a national intervention in Botswana improved same-day ART initiation for people newly diagnosed with HIV
Top 5 HIV treatment stories from CROI 2022
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV
Large disparities in dolutegravir uptake persist between men and women in low and middle-income countries
Dolutegravir more likely to suppress very high viral loads than other recommended first-line drugs
